# Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma

> **NCT01870609** · PHASE2 · TERMINATED · sponsor: **Verastem, Inc.** · enrollment: 344 (actual)

## Conditions studied

- Malignant Pleural Mesothelioma

## Interventions

- **DRUG:** defactinib (VS-6063)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01870609
- **Lead sponsor:** Verastem, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-09
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 344 (ACTUAL)
- **Why stopped:** Interim analysis-DSMB stated good safety profile but lack of efficacy
- **Last updated:** 2017-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01870609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01870609, "Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01870609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*